Addex gets $1M MJFF grant to test potential dyskinesia drug

03/20/2013 | Pharmaceutical Business Review Online

The Michael J. Fox Foundation awarded Addex Therapeutics a $1 million grant to support clinical trials of dipraglurant against levodopa-induced dyskinesia among Parkinson's disease patients. Dipraglurant, an oral, small molecule allosteric modulator, selectively inhibits metabotropic glutamate receptor 5.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT